Poster# PE9/49

Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Adults Aged ≥ 65 Years: Week 48 Results from a Phase 3b, Open-Label Trial (GS-US-380-4449)

F Maggiolo[1], G Rizzardini[2], JM Molina[3], F Pulido[4], S De Wit[5], L Vandekerckhove[6], J Berenguer[7], C Blair[8], S Chuck[8], D Piontkowsky[8], H Martin[8], I McNicholl[8], R Haubrich[8], J Gallant[8]

[1]Division of Infectious Diseases, ASST Papa Giovanni XXIII, Bergamo, Italy; [2]Division of Infectious Diseases, Luigi Sacco Hospital, ASST Fatebenefratelli Sacco, Milan, Italy; [3]Department of Infectious Diseases, Saint Louis Hospital, University Paris Diderot, France; [4]Unidad VIH, Hospital Universitario 12 de Octubre, imas12, UCM, Madrid, Spain; [5]St Pierre University Hospital, Université Libre de Bruxelles, Brussels, Belgium; [6]University Hospital Ghent, Belgium; [7]Infectious Diseases, Hospital General Universitario Gregorio Marañón (IiSGM), Madrid, Spain; [8]Gilead Sciences, Foster City, CA, USA

Gilead Sciences, Inc.
333 Lakeside Drive
Foster City, CA 94404
Tel: (650) 522-6009
Fax: (650) 522-5260

Background

- Because almost 50% of people living with HIV are > 50 years old, collecting and evaluating data on long term safety in older patients is important.
- Older individuals are at increased risk of co-morbidities and polypharmacy, so ensuring the safety and convenience of ART in this population is critical.
- B/F/TAF is a small single-tablet regimen with few drug-drug interactions and a high barrier to resistance.
- Tenofovir alafenamide (TAF) is a prodrug of tenofovir associated with 90% lower tenofovir plasma levels than tenofovir disoproxil fumarate (TDF), resulting in less renal and bone toxicity.

Methods

Study Design

Multicenter, open-label, 96-week single arm



Study sites in Belgium, France, Italy, Spain and the United Kingdom

Primary endpoints:
- HIV RNA < 50 copies/mL at Week 24 by FDA Snapshot algorithm

Secondary endpoints:
- HIV-1 RNA <50 copies/mL at Week 48 and Week 96
- Safety and tolerability of B/F/TAF through 96 weeks

Key Inclusion Criteria

- Age ≥ 65 years at screening
- Currently receiving an antiretroviral regimen of E/C/F/TAF single tablet regimen (or FTC/TDF + 3rd agent if current or past participant in GS-US-292-1826) for ≥ 3 months
- Documented plasma HIV-1 RNA < 50 copies/mL on current regimen for the last 2 visits preceding the Screening Visit
  - Transient detectable viremia or "blips" (HIV-1 RNA ≥ 50 and < 400 copies/mL) were acceptable
- Estimated GFR ≥ 30 mL/min (Cockcroft-Gault formula)

Results

Baseline Demographics and Disease Characteristics

	B/F/TAF N=86
Median age, years (range)	69 (65-80)
Female, % (n)	13% (11)
Race, %, (n)*	
White	99% (82)
Black	1% (1)
Ethnicity, Hispanic/Latino	14% (12)
Median weight (kg) (range)	78 (49-110)
Median estimated GFR_{CG}, mL/min (range)	76 (40-130)

* 3 participants did not disclose race

Results, cont'd

Baseline Demographics and Disease Characteristics, cont'd

	B/F/TAF N=86
Mode of Infection	
MSM (n)	46.5% (40)
Heterosexual (n)	46.5% (40)
HIV RNA < 50 copies/mL at baseline	98% (84)
Median CD4 count, cells/mm³ (range)	676 (132-1385)
Baseline Regimen (n)	
EVG/COBI/FTC/TAF	92% (79)
RPV/FTC/TDF	5% (4)
EFV/FTC/TDF	1% (1)
EVG/COBI/FTC/TDF	1% (1)
NVP+FTC/TDF	1% (1)
Chronic Non-ARV Medications at Baseline, median (IQR)	3.0 (2, 5)
Baseline Chronic Medications by organ-system class	
Cardiovascular system	64% (55)
Gastrointestinal tract	63% (54)
Nervous system	44% (38)
Blood and blood forming organs	27% (23)
Musculoskeletal system	23% (20)
Genitourinary system and sex hormones	21% (19)

Virologic Outcomes at Week 48 (Snapshot Analysis)



- No participant had a HIV viral load ≥ 50 c/mL.
- At Week 60 M=E, 100% (83/83) had HIV RNA < 50 c/mL.
- Median change in CD4 count was 22 cells/mm³ (IQR: -54, 94) at W48.

Virologic Outcomes at Week 48 by FDA Snapshot

	B/F/TAF N=86
HIV-1 RNA < 50 c/mL	78 (91%)
HIV-1 RNA ≥ 50 c/mL	0
HIV-1 RNA ≥ 50 c/mL in W48 Window	0
DC Study Drug Due to Lack of Efficacy	0
DC Study Drug Due to AE and Last Available HIV-1 RNA ≥ 50 c/mL	0
DC Study Drug Due to Other Reasons and Last Available HIV-1 RNA ≥50 c/mL	0
No Virologic Data in W48 Window	8 (9%)
DC Study Drug Due to AE and Last Available HIV-1 RNA < 50 c/mL	3 (3.5%)*
DC Study Drug Due to Other Reasons and Last Available HIV-1 RNA < 50 c/mL	0
Missing Data During Window but on Study Drug	5†

*1) abdominal discomfort (grade 2, drug-related) 2) alcohol withdrawal 3) benzodiazepine withdrawal
† At W60, all 5 participants had an HIV-1 RNA < 50 c/mL
c/mL=copies/mL, DC=discontinued

Treatment-Emergent Adverse Events through Week 48

	B/F/TAF (n=86) % (n)
Any Grades 2-4 Study Drug-Related AE	2.3% (2)
Any Grades 3-4 Study Drug-Related AEs	0
Grades 3 or 4 Laboratory Abnormalities	8% (7)
Any Study Drug-Related Serious AE	0
AEs Leading to Study Drug Discontinuation	3.5% (3)*
AEs Leading to Study Drug Discontinuation (drug-related)	1% (1)
Death	0

*1) abdominal discomfort (grade 2, drug-related) 2) alcohol withdrawal 3) benzodiazepine withdrawal

- There were no renal, bone or hepatic discontinuations

Weight: Median Change from Baseline through Week 48



- Median change in weight at Week 48 was 0.1 kg (IQR -1.0, 2.3)

Renal Biomarker Changes (%) at Week 48



*RBP:Cr, retinol-binding protein/creatinine; β2m:Cr, urine beta-2-microglobulin/creatinine

- 8% of participants switched from a TDF-based regimen to B/F/TAF

Estimated Glomerular Filtration Rate: Median Changes from Baseline through Week 48



$eGFR_{CG}$, estimated glomerular filtration rate calculated with Cockcroft-Gault equation

- eGFR decline is consistent with known inhibition of OCT2 creatinine transporter

Changes in Fasting Lipids at Week 48



LDL-low-density lipoprotein, HDL-high-density lipoprotein

- Participants on lipid-modifying medication
  - At baseline: n=36 (42%)
  - Initiated during study: n=3 (3.5%)

Conclusion

- Switching to B/F/TAF is safe, effective and well tolerated in virologically suppressed adults ≥ 65 years through 48 weeks
  - High virologic suppression at 91% with no virologic failures and no treatment-emergent resistance
  - No renal, bone, or hepatic AEs resulting in discontinuation
  - Few drug-related AEs leading to discontinuation (1/86)
  - No drug-related AEs that were serious or Grade 3 or 4
  - Median weight was stable
  - Fasting lipid parameters all decreased
  - eGFR decline is consistent with known inhibition of OCT2 creatinine transporter

Acknowledgments: We extend our thanks to the participants, their partners and families, and all GS-US-380-4449 Investigators

F Ajana, A Antinori, J Berenguer, JI Bernardino de la Serna, A Bonjoch, E Cua, S de Wit, A Di Biagio, G Di Perri, C Duvivier, PM Girard, E Lazaro, G Madeddu, F Maggiolo, J Mallolas Masferrer, GM Mateo García, B Menzaghi, JM Molina, P Morlat, C Mussini, J Navarro, E Ong, G Parruti, B Payne, J Perez Stachowski, P Philibert, L Piroth, F Pulido, T Quirino, F Raffi, G Rizzardini, JD Ross, D Salmon-Ceron, L Vandekerckhove, L Waters

This study was funded by Gilead Sciences, Inc.